Cryo-Cell International (CCEL)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	197.44 k	197.44 k	197.44 k	197.44 k	197.44 k	197.44 k
Cash burn (monthly)	90.59 k	32.21 k	(no burn)	1.04 mm	(no burn)	(no burn)
Cash used (since last report)	340.52 k	121.09 k	n/a	3.91 mm	n/a	n/a
Cash remaining	-143.08 k	76.35 k	n/a	-3.72 mm	n/a	n/a
Runway (months of cash)	-1.6	2.4	n/a	-3.6	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2024

CCEL institutional ownership history Ownership history

12.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	15	13	+15.4%
Opened positions	4	3	+33.3%
Closed positions	2	3	-33.3%
Increased positions	2	3	-33.3%
Reduced positions	2	3	-33.3%

13F shares	Current	Prev Q	Change
Total value	6.52 bn	4.77 bn	+36.6%
Total shares	1.07 mm	1.03 mm	+4.3%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Hamilton Lane Advisors	409.73 k	$3.06 bn	0.0%
Iszo Capital	195.03 k	$0.00	0.0%
SFI Advisors	165.30 k	$1.23 bn	0.0%
Massmutual Trust Co FSB	111.04 k	$828.32 mm	-2.8%
Vanguard	92.94 k	$693.33 mm	+2.0%
NTRS Northern Trust	23.38 k	$174.40 mm	-11.1%
Geode Capital Management	21.43 k	$159.93 mm	NEW
Cerity Partners	19.56 k	$145.94 mm	0.0%
Rowland & Co Investment Counsel	14.43 k	$107.67 mm	NEW
BLK BlackRock	12.93 k	$96.49 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Geode Capital Management	21.43 k	+21.43 k	NEW
Rowland & Co Investment Counsel	14.43 k	+14.43 k	NEW
BLK BlackRock	12.93 k	+12.93 k	NEW
Massmutual Trust Co FSB	111.04 k	-3.18 k	-2.8%
NTRS Northern Trust	23.38 k	-2.92 k	-11.1%
Vanguard	92.94 k	+1.80 k	+2.0%
UBS UBS	0.00	-741.00	EXIT
RY Royal Bank of Canada	74.00	+74.00	NEW
JPM JPMorgan Chase & Co.	11.00	+2.00	+22.2%
BAC Bank of America	0.00	-2.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CCEL insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
12 Nov 24	Oleg Mikulinsky	Common Stock	Option exercise	Acquire M	No	No	4.34	10,000	43.40 k	104,349
12 Nov 24	Oleg Mikulinsky	Common Stock	Option exercise	Acquire M	No	No	3.2	10,000	32.00 k	94,349
12 Nov 24	Oleg Mikulinsky	Stock Option Common Stock	Option exercise	Dispose M	No	No	4.34	10,000	43.40 k	0
12 Nov 24	Oleg Mikulinsky	Stock Option Commpn Stock	Option exercise	Dispose M	No	No	3.2	10,000	32.00 k	0
29 Oct 24	Berger Harold D.	Stock Option Common Stock	Grant	Acquire A	No	No	5.82	5,300	30.85 k	5,300
22 Dec 23	Portnoy David	Stock Option Common Stock	Grant	Acquire A	No	No	6.47	50,000	323.50 k	50,000
22 Dec 23	Oleg Mikulinsky	Stock Option Common Stock	Grant	Acquire A	No	No	5.88	10,000	58.80 k	10,000
22 Dec 23	Jill M Taymans	Stock Option Common Stock	Grant	Acquire A	No	No	5.88	10,000	58.80 k	10,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Cryo-Cell International Q3 2024 GAAP EPS $0.13 Beats $0.02 Estimate, Sales $8.07M Beat $7.98M Estimate

15 Oct 24

Cryo-Cell International (NASDAQ:CCEL) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.02 by 550 percent. This is a 62.5 percent increase over earnings of $0.08 per share

Press releases

From Benzinga Pro

Cord Blood Banking Leader Cryo-Cell Declares Initiation of Regular Quarterly Cash Dividend

30 Oct 24

Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2024 Financial Results

15 Oct 24

Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended